Du är här


Active Biotech: Annual Report 2013 Active Biotech AB (publ)

Active Biotech's Annual Report 2013 (in Swedish) is now available for download
atwww.activebiotech.com. The English version will be available within short.

The Annual Report will only be digitally distributed.

Lund, April 7, 2014
Active Biotech AB (publ)
Tomas Leanderson

For further information, please contact:
Hans Kolam
Tel +46 (0)46 19 20 44

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal
phase are laquinimod (Nerventra®), an orally administered small molecule with
unique immunomodulatory properties for the treatment of multiple sclerosis,
tasquinimod for prostate cancer and ANYARA primarily for the treatment of
renal cell cancer. In addition, laquinimod Phase II clinical trials in
Crohn's and Lupus has been concluded. The company also has one additional
project in clinical development, the orally administered compound paquinimod
(57-57) for systemic sclerosis. Please visitwww.activebiotech.comfor more

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted
for publication at 10:00 a.m. CET on April 7, 2014.

Årsredovisning 2013 Active Biotech AB (publ)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.